Kiora Pharmaceuticals Inc Overview
Industry: Pharmaceuticals
Sector: Healthcare
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California. Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Kiora Pharmaceuticals Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $1.2M (+0% YoY). Net loss was -$2.1M (-3% YoY).
Revenue
$1.2M
+0% YoY
Net loss
-$2.1M
-3% YoY
What changed
- Revenue +0% YoY to $1.2M.
- Net loss -3% YoY to -$2.1M.
Guidance / outlook
We expect the last patient, first visit in the first quarter of 2027 with topline data in the third quarter of 2027. Kiora is responsible for conducting the ABACUS-2 trial, with development costs fully reimbursed under its collaboration with Théa Open Innovation, who holds exclusive rights to develop and commercialize KIO-301 in the U.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
Aug 07, 2026
SEC filing
8-K
Aug 07, 2026
SEC filing
8-K
May 08, 2026
SEC filing
10-Q
May 08, 2026
Earnings release
Earnings release
May 08, 2026
SEC filing
10-K
Mar 25, 2026
SEC filing
8-K
Mar 25, 2026
Earnings release
Earnings release
Mar 25, 2026
SEC filing
10-Q
Nov 07, 2025
SEC filing
8-K
Nov 07, 2025
Earnings release
Earnings release
Nov 07, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
KPRX 10-Q & SEC Filings
Headline from Yahoo Finance: KPRX 10-Q & SEC Filings.
Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com
Headline from Investing.com Canada: Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com.
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Headline from Yahoo Finance: Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update.
Earnings Per Share
Score 5.00/5
Kiora Pharmaceuticals Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Pharmaceuticals industry
, PharmaCyte Biotech Inc
, Abcam PLC
, RVL Pharmaceuticals PLC
are companies with high ratings.
Return on Equity
Score 0.52/5
Kiora Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 1.18/5
Kiora Pharmaceuticals Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 2.52/5
Kiora Pharmaceuticals Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios